In human studies, low COMT (catechol-Omethyltransferase) activity has been associated with increased sensitivity to acute clinical preoperative or postoperative pain. We explored the association between the COMT genotype and three chronic pain conditions: migrainous headache, fibromyalgia, or chronic widespread pain and chronic musculoskeletal pain. Furthermore, we evaluated whether COMT genotype affects the efficacy of opioids in chronic pain. After a systematic literature review, we carried out meta-analyses on the three chronic pain conditions. The efficacy of opioids was evaluated using a systematic review only. The meta-analyses showed that fibromyalgia or chronic widespread pain is the only type of chronic pain that could be associated with the COMT single nucleotide polymorphism rs4680 (Val158Met). Met158, which results in the low-activity variant of COMT, is the risk allele. In chronic clinical pain, the effect of the COMT polymorphism depends on the pain condition. Low COMT activity is not associated with migrainous headache or chronic musculoskeletal pain conditions, but it may increase the risk for fibromyalgia or chronic widespread pain. Low COMT activity increases opioid receptors and enhances opioid analgesia and adverse effects in some cancer pains. Findings from animal studies that have utilized COMT inhibitors elucidate the mechanism behind these findings. In rodent pain models, COMT inhibitors are pronociceptive, except for neuropathic pain models, where nitecapone was found to be antiallodynic. The complex interplay between enhanced adrenergic and dopaminergic activity in different parts of the nociceptive system probably explains the complicated actions of low COMT activity.
Introduction

General
Several general factors can explain why catechol-Omethyltransferase (COMT) activity is associated with pain. First, COMT is one of the regulators of extracellular catecholamine concentrations, especially in prefrontal brain areas and peripheral tissues, and catecholamines in turn affect the pain tract at several levels. Second, there is some evidence that polymorphisms of the COMT gene, some of which substantially affect COMT activity, may affect pain perception and a patient's ability to cope with pain. Third, compounds that inhibit COMT activity modify pain responses primarily by preventing the metabolism of catecholamines; however, COMT inhibitors could have their own properties, such as the alleviation of oxidative stress, which could interfere in at least some forms of pain.
In the brain areas with a high dopamine transporter density, such as the striatum, uptake 1 into dopamine nerve terminals by dopamine transporter is the primary mode of terminating the dopamine signal, and COMT plays a minor role [1] [2] [3] [4] . In contrast, in brain areas with a low dopamine transporter density [5] , for example in the prefrontal cortex, uptake 2 into postsynaptic neurons or non-neuronal cells [6] [7] [8] , followed by metabolism by COMT [9] and uptake by the noradrenaline transporter [4, [10] [11] [12] [13] [14] appear to control the dopaminergic transmission. Therefore, changes in the brain COMT activity are reflected mainly in functions that are dependent on the prefrontal cortex [1] [2] [3] [4] 14, 15] .
The COMT gene [COMT (human gene), Comt] codes for soluble (S-COMT) and membrane-bound (MB-COMT) COMT protein isoforms [16, 17] . The COMT gene harbors dozens of single nucleotide polymorphisms (SNPs) and at least six of the most frequently occurring SNPs have been investigated for their association with human pain perception. One SNP (rs2075507) is located in the estrogen-sensitive portion of the MB-COMT promoter region, and the second (rs6269) is located in the promoter region of S-COMT [18] . The next three SNPs (rs4633, rs4818, and rs4680) are in the coding region of both S-COMT and MB-COMT. The sixth SNP (rs165599) is located at the end of the 3 0 -UTR of the gene [19] . Variations in SNPs rs4633 and rs4818 are synonymous whereas the variation in SNP rs4680 is nonsynonymous and codes for a substitution of valine (Val) to methionine (Met) at codon 158 for MB-COMT and at codon 108 for S-COMT. This scenario produces an enzyme with a lower thermostability, which results in decreased enzyme activity under physiological conditions. This Val158Met polymorphism, which governs the level of COMT activity [20, 21] , has been linked to several mental diseases, such as schizophrenia, in which the cortical dopaminergic function is important [22] [23] [24] [25] . This systematic review and meta-analysis explores the association between the COMT genotype and certain chronic pain conditions: migrainous headache, fibromyalgia or chronic widespread pain, and chronic musculoskeletal pain. We also investigated, by means of a systematic and narrative review, whether the COMT genotype affects the opioid response in chronic pain patients. The results from the meta-analyses show that fibromyalgia or chronic widespread pain is the only type of chronic pain that may be associated with COMT SNP rs4680.
Catechol-O-methyltransferase activity and pain in animal studies
The effects of altered COMT activity on pain have been characterized using genetically modified mice [26, 27] . The mouse lines include Comt knockout mice in which the Comt gene has been rendered inactive [28] and transgenic mice that locally overexpress the Val158 variant of the human COMT gene in the prefrontal cortex (COMT Val-tg [27] ). In addition, the impact of COMT activity on pain sensation has been studied using normal mice and rats that were administered COMT inhibitors [29] [30] [31] [32] . New selective COMT inhibitors undoubtedly interfere with pain perception [29, 30, 32] .
The COMT Val-tg mice that overexpress the human highactivity COMT variant in the prefrontal cortex show diminished sensitivity to painful stimuli in tail flick and hot plate tests [27] . In agreement with this finding, homozygous Comt knockout mice that completely lack COMT activity showed increased pain sensitivity [27] . However, in our study, which also utilized the same tests, the pain sensitivity of homozygous knockout mice with no COMT activity and heterozygous knockout mice with 50% of the wild-type COMT activity did not differ from that of their wild-type littermates [26] .
In acute pain models, COMT inhibitors such as OR-486 (3,5-dinitrocatechol; 30 mg/kg, intraperitoneally) and tolcapone (Ro 41-0960; 30 mg/kg, intraperitoneally) have been pronociceptive [29, 30, 32] , and they have sensitized the rats to mechanical and thermal nociceptive stimuli [29, 30] . The same effect was observed in mice after the administration of different types of COMT inhibitors [32] .
Nitecapone, a COMT inhibitor, partially prevented the development of allodynia in two different neuropathic pain models in the rats: the diabetic neuropathy [31, 33] and the spinal nerve ligation model.
Methods
The questions we wanted to answer were as follows: Do COMT polymorphisms (rs4680 and others) affect the risk of chronic pain conditions? Do they affect the response to analgesic treatments in chronic pain? Systematic searches were performed utilizing Pubmed and the ISI Web of Science, which were limited to human studies and covered articles published in English, French, German, Spanish, Italian, Portuguese, Swedish, Norwegian, Danish, Estonian, or Finnish, and were published or in press before 31 December 2011. We did not have access to any unpublished studies. We excluded abstracts, conference proceedings, case studies, reviews, and textbook chapters. We also hand-searched the reference lists for all retrieved studies and relevant review articles. The initial search terms were 'catechol-O-methyltransferase' and 'chronic pain'. The papers that were retrieved from this search discussed several different chronic pain conditions including chronic musculoskeletal complaints or pain, chronic widespread pain, fibromyalgia, headache, postoperative pain in lumbar degenerative disc disease, postoperative shoulder pain, and temporomandibular joint disorder. On the basis of these findings, we performed the following searches: 'Catechol-O-methyltransferase' and 'Musculoskeletal pain'; 'Catechol-Omethyltransferase' and 'Chronic widespread pain'; 'Catechol-O-methyltransferase' and 'Fibromyalgia'; 'Catechol-O-methyltransferase' and 'Headache'; 'Catechol-O-methyltransferase' and 'Postoperative pain'; 'Catechol-O-methyltransferase' and 'Temporomandibular joint disease'. In addition, we decided to search for certain other chronic pain conditions that seemed to be missing: 'Catechol-O-methyltransferase' and 'Cancer pain', 'Catechol-O-methyltransferase' and 'Neuropathic pain', 'Catechol-O-methyltransferase' and 'Back pain' as well as 'Catechol-O-methyltransferase' and 'Arthritis'. Furthermore, we were aware that the association between the COMT genotype and the effect of opioids had been studied and, therefore, we performed one more literature search with the terms 'Catechol-O-methyltransferase' and 'Opioids'. Both authors evaluated the material independent of each other. Articles were selected in the following two stages: titles and abstracts, followed by full-text articles. Duplicate studies were excluded.
The following information was abstracted from each study: first author, year of publication, phenotype, COMT polymorphism in question, number of participants, number of cases and controls, sex distribution, ethnicity of participants, enrollment strategy, minor allele frequency, DNA source, genotyping method, Hardy-Weinberg equilibrium (HWE), matching of cases and controls on the basis of ethnicity, mental conditions, and the main finding of the study. Studies were included in this review if they fulfilled the following criteria: (a) relevant phenotype studied [chronic headache, chronic musculoskeletal pain (fibromyalgia, chronic widespread pain, temporomandibular joint disorder, chronic low back pain, persistent postoperative pain), neuropathic pain, opioid response, or adverse effects of opioid treatment in chronic pain] and (b) adequate scientific quality (HWE analyzed, allele frequencies given, reasonable statistics, appropriate control group included, no population stratification reported). In some cases, the authors of the original articles were contacted for clarifications and supplementary information. Failure to report HWE was not an absolute exclusion criterion, but a thorough evaluation of the potential reasons for deviation was required for inclusion if the control group was not in HWE. If the authors did not carry out HWE analysis, we calculated it on the basis of the data given using an online calculator (http://www.oege.org/software/hwe-mr-calc.shtml [34] ). When possible, w 2 analyses, odds ratios (OR), and 95% confidence intervals (CIs) were also calculated for associations between the COMT polymorphism and the chronic pain phenotype if they were not given by the authors. In addition, the power was calculated using G*Power 3.1.2 software (Heinrich Heine University, Düsseldorf, Germany [35] ). Because the effects of most gene polymorphisms are minor [36] , the power analyses were based on an assumption of a small effect size (0.1). Figure 0.1 refers to Cohen's effect size measures, which he grouped into effect size conventions ('small' 0.1-0.3; 'medium' 0.3-0.5; and 'large' 0.5-0.8 [37] ). Table 1 lists the studies that were included in or excluded from the review after the initial literature search.
We continued the analysis by carrying out meta-analyses of the associations between the COMT Val158Met genotype and migrainous headache, fibromyalgia, or chronic widespread pain and musculoskeletal pain. Unfortunately, material on morphine response in chronic pain and morphine withdrawal symptoms was found to be too heterogeneous for a meta-analysis.
Phenotypes were grouped as follows: meta-analysis I: migrainous headache, including both migraine with aura and migraine without aura. Meta-analysis II: Fibromyalgia and chronic widespread pain, defined according to the criteria of American College of Rheumatology. (Chronic widespread pain is the cardinal symptom of fibromyalgia.) Meta-analysis III: Chronic musculoskeletal pain conditions, including low back pain, osteoarthritis-related pain, upper limb and neck discomfort, and myofacial pain.
We were also prepared to carry out meta-analyses of other COMT SNPs and haplotypes. However, the number of papers within each chronic pain condition group was not sufficient to study the associations between matching COMT haplotypes or SNPs other than rs4680. At least three papers were required for the meta-analyses. All of the articles that were eligible for the systematic review were included in the meta-analyses, provided that sufficient data were presented. The analyses were performed using Comprehensive Meta-Analysis Version 2 software (Biostat, Englewood, New Jersey, USA). A codominant genetic model was chosen because Val158 and Met158 alleles determine human COMT activity codominantly [75] [76] [77] . We used a random effects model that accounts for the heterogeneity found between the studies. Between-study heterogeneity was assessed using Cochran's Q (significant at P < 0.05) and I 2 tests (25% = low heterogeneity, 50% = moderate heterogeneity, 75% = high heterogeneity [78] ).
One concern when carrying out a meta-analysis is the potential for publication bias, in which small and statistically nonsignificant studies may remain unpublished. This scenario, in turn, would result in overestimation of the effect sizes in a meta-analysis of published studies. We used two statistical methods, Duval and Tweedie's trim and fill test and funnel plots, followed by Egger's regression method (publication bias considered significant at P < 0.05) and Begg and Mazumdar's rank correlation test (publication bias considered significant at P < 0.05) to address this problem. Duval and Tweedie's trim and fill test calculates how the effect size would shift if the apparent bias was removed [79, 80] . Funnel plots are plots of a measure of study size on the y-axis as a function of effect size on the x-axis. Larger studies are found at the top of the graph usually closer to the mean effect size, whereas smaller studies are found closer to the bottom of the graph scattered across a wider range of values. In the absence of publication bias, the studies included in the funnel plot are distributed symmetrically around the mean effect size. Symmetricity is verified by Egger's regression test and Begg and Mazumdar's rank correlation test.
Results
General considerations
During the last phase of the data extraction, 10 articles were excluded from further analysis because of a failure to fulfill our inclusion criteria ( Table 1 ). The most common reason was that the paper did not actually report an association between the COMT rs4680 and chronic pain condition. One article reported results that were already published in an earlier study and another was rejected because of a lack of HWE in the control group. Five articles could not be included in the meta-analyses because there were too few articles (one or two) on that specific pain condition (nonmigrainous headache, neuropathic pain, multisomatoform disorder, and persistent postsurgical pain) to carry out a meta-analysis. We could not carry out a meta-analysis on the opioid response studies because of the general heterogeneity of the published material. Instead, the opioid studies were reviewed in a traditional narrative manner. Altogether, 15 gene association studies on COMT and chronic pain were included in the meta-analyses. These studies included three papers on migrainous headache, eight papers on fibromyalgia or chronic widespread pain, and four papers on musculoskeletal pain conditions. The majority of the papers that were eligible for metaanalysis had studied Caucasian populations, including rs4646312, overall 60% rs4680, overall 47%
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Hispanic Caucasians (Belgian, Brazilian, British, Canadian, Dutch, Estonian, Finnish, German, Hungarian, Irish, Italian, Lithuanian, Mexican, Norwegian, Polish, Spanish, Swedish, and Swiss). One report studied Koreans and another report studied Israelis; three reports studied Turks. The majority of papers had studied both sexes. However, four studies were performed on only women. One study did not report the sex distribution. On average, 58% of the participants were women in those studies that included both sexes. The percentage of women was somewhat higher in the cases (62%) than in the controls (55%).
Most of the studies had a relatively small sample size and, thus, weak statistical power. Our estimate of the statistical power may be considerably lower than that of the authors of some studies because we used the assumption of a small effect size and calculated the power for w 2 contingency tables that were the basis of the metaanalyses. This assumption was based on studies showing that the relative risks of genetic factors for multigenetic diseases are small [36, 81] .
Migrainous headache and rs4680
The meta-analysis of three studies showed that migrainous headache is not associated with rs4680 (OR 0.95, 95% CI 0.81-1.11, P = 0.5, n = 2901; Fig. 1 ). Heterogeneity tests did not find heterogeneity in these data (Q = 1.723, d.f. = 2, P = 0.4, I 2 = 0%). Publication bias tests suggested that it is unlikely that the result would be biased because of missing studies. Duval and Tweedie's trim and fill test suggested no adjustments for the number of studies and the funnel plot was symmetrical (Egger's test, P = 0.3; Begg and Mazumdar's rank correlation test, P = 0.06).
Fibromyalgia or chronic widespread pain and rs4680
The meta-analysis of eight studies showed that rs4680 is likely to be associated with fibromyalgia or chronic widespread pain (Fig. 2a) . The OR for the Met allele being a risk allele for fibromyalgia or widespread pain was 1.28, 95% CI 1.06-1.55, P = 0.01, n = 3811. One study [47] was excluded because of the lack of HWE in the control group.
Heterogeneity tests found significant heterogeneity in these data (Q = 19.15, d.f. = 8, P = 0.01, I 2 = 58%). We examined the role of ethnicity in heterogeneity by dividing the studies into three groups: Non-Hispanic Caucasians, Hispanic Caucasians, and Middle East populations. The Middle East group consisting of Israelis and Turks showed a significant association between rs4680 and fibromyalgia or chronic widespread pain (Fig. 2b, OR 1 .38, 95% CI 1.07-1.79, P = 0.01, n = 1015), and heterogeneity was low (Q = 2.58, d.f. = 2, P = 0.3; I 2 = 23%). The Hispanic Caucasian group also showed a significant association between rs4680 and fibromyalgia or chronic widespread pain (Fig. 2c , OR 1.69, 95% CI 1.17-2.46, P = 0.006, n = 350), and low heterogeneity (Q = 2.89, d.f. = 2, P = 0.2; I 2 = 29%), although the sample was small. In the NonHispanic Caucasian group, in contrast, rs4680 was not associated with fibromyalgia or chronic widespread pain (Fig. 2d , OR 1.06, 95% CI 0.93-1.20, P = 0.4, n = 2410). Heterogeneity was very low within this group (Q = 0.66, d.f. = 2, P = 0.7; I 2 = 0%).
Publication bias tests suggested that it is unlikely that the result would be biased because of missing studies. Duval and Tweedie's trim and fill test suggested no adjustments for the number of studies and the funnel plot was symmetrical (Egger's test, P = 0.06; Begg and Mazumdar's rank correlation test, P = 0.1).
Musculoskeletal pain conditions and rs4680
The meta-analysis of four studies showed that musculoskeletal pain conditions are not associated with rs4680 (OR 1.01, 95% CI 0.76-1.34, P = 1.0, n = 6327; Fig. 3 ). Heterogeneity tests found significant heterogeneity in these data (Q = 8.76, d.f. = 3, P = 0.03, I 2 = 67%). Hagen et al. [39] Park et al. [40] Statistics for each study
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Publication bias tests suggested that it is unlikely that the result would be biased because of missing studies. Duval and Tweedie's trim and fill test suggested no adjustments for the number of studies and the funnel plot was symmetrical (Egger's test, P = 0.4; Begg and Mazumdar's rank correlation test, P = 0.5).
Discussion
Meta-analyses
The main finding of the present meta-analyses is that the Met allele of rs4680 SNP of the COMT gene seems to be associated with an elevated risk of fibromyalgia or chronic widespread pain. This effect is observed in several Caucasian populations and also in Israelis and Turks. Ethnicity seems to affect this association in such a way that Non-Hispanic Caucasians do not show an association between rs4680 and fibromyalgia or chronic widespread pain. The excluded study of Barbosa et al. [47] also suggests that fibromyalgia and pain sensitivity are associated with rs4680 in a Brazilian Caucasian population that is essentially a mix of Hispanic Caucasians, Brazil's indigenous peoples, and Africans. In addition, two reports that were not included in the meta-analysis suggested that there is a moderating role for rs4680 in behaviors that were related to fibromyalgia pain. These studies showed that rs4680 moderates the relation of daily maladaptive coping as well as the effect of pain on the positive affect in fibromyalgia patients [49, 50] .
Our finding of a significant association between rs4680 and fibromyalgia or chronic widespread pain is at odds with the meta-analysis of Lee et al. [82] . Our metaanalysis included all those studies that were in their analysis and, in addition, four additional studies on the basis of our different inclusion criteria (diagnoses included both fibromyalgia and chronic widespread pain; languages included Portuguese and literature searches spanned to the end of the year 2011). These additional studies apparently contributed toward the differential end result.
Although migrainous headache is obviously not associated with rs4680, it might still affect the risk of other chronic headaches or the phenotype of the migraine. Hagen et al. [39] suggested that Met is the risk allele for nonmigrainous headache in Norwegian women. Park et al. [40] showed that female Korean migraine patients suffer from more severe headache, nausea, and vomiting if they are Met carriers. Because COMT contributes toward estrogen metabolism, and estrogen is involved in the pathophysiology of migraine, it is likely that COMT polymorphisms affect the risk of migraine in a way that has not yet been thoroughly explored.
The meta-analysis on chronic musculoskeletal complaints did not show an association between rs4680 and musculoskeletal pain. However, COMT SNP rs4633 may modulate postsurgical improvement of the disability index score [43] . In addition, COMT pain sensitivity haplotypes affect pain ratings together with pain catastrophizing ratings, again suggesting a modulatory role for COMT in chronic pain [42] . The studies that are included in the meta-analysis of the chronic musculoskeletal complaints showed controversial results. The inconsistencies might result from the fact that the studies focused on different pain conditions; although the conditions are similar in a wider sense, their mechanisms may still differ from each other. One of the studies that we counted in the meta-analysis actually dealt with patients with very different musculoskeletal problems, ranging from elbow or shoulder pains to muscle-derived chest or abdominal pain [68] . The apparent problems in the meta-analysis of the chronic musculoskeletal References
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complaints reflect the overall problem of there being only a few studies of each pain type. The inclusion of different pain conditions of similar type in one analysis may yield very heterogeneous results. Additional and possibly better-defined replications of the existing studies would considerably benefit future meta-analyses and add to their power.
Studies included only in the systematic review Opioid response in chronic pain
Several different studies have explored the effects of COMT genotypes and opioid responses or the adverse effects of opioids in patients who have either cancer or other types of chronic pain. Because of considerable differences in the experimental setup (exact polymorphisms or haplotypes studied, phenotypes studied, form of data presented) and repeated analyses of the same cohort, we could not carry out a meta-analysis on the association between opioid effects and COMT polymorphisms. Instead, here, we present a short, traditional review of the association of opioid responses and COMT polymorphisms.
The pioneering positron emission tomography study by Zubieta et al. [83] in healthy human volunteers showed that a low COMT activity allele (Met158) increases the availability of the m-opioid receptors, analyzed as a binding potential of [ 11 C]carfentanil in the anterior thalamus and thalamic pulvinar. This upregulation has been later verified by studies using human post-mortem tissue [84] . In an experimental pain study, rs4680 did not affect the acute analgesic response to a low dose of remifentanil [85] . Instead, the carriers of Met158Met-allele were more sensitive to the pain than the Val158Met or Val158Val carriers 1 h after a single opioid administration, and thus showed an enhanced opioid-induced hyperalgesia.
Supporting the results of Zubieta et al. [83] , Rakvåg et al. [62] suggested that Caucasian cancer patients with the Val158Val genotype of rs4680 required more morphine than the Met158 carriers to achieve the same level of analgesia. Val158Val carriers also showed higher concentrations of both morphine and morphine glucuronides than Val158Met or Met158Met carriers. The effect of the Met158Met genotype is further enhanced in patients with an Asp40Asp genotype of the m-opioid receptor gene OPRM1 rs1799971 SNP (Asn40Asp) [64] . The carriers of a common haplotype, including the Met158 allele of rs4680, required less morphine than the noncarriers [63] . Similarly, Kolesnikov et al. [66] showed that patients who were heterozygous both for Asn40Asp and for Val158Met consumed less opioids and experienced less nausea and sedation during recovery from acute postsurgical pain than patients with the Asn40Asn genotype. However, no Asp40Asp + Met158-Met carriers were identified. The COMT genotype has also been linked to drowsiness and confusion, caused by morphine treatment [65] . However, it was not rs4680 but rs740603 and haplotypes containing several SNPs in intron 1 that were associated with adverse effects.
Subsequent studies could not confirm the role of the COMT polymorphism in opioid responses. Klepstad et al. [60] studied cancer patients, and suggested that both rs4646312 and rs4680 are associated with opioid dose requirements. In contrast to the findings of Rakvåg et al. [62] , Met158Met and Val158Met carriers showed higher median opioid doses per day than the Val158Val carriers. However, this finding was not replicated in the validation sample. Lötsch et al. [61] failed to find an association between rs4680 and the opioid dose or adverse events in chronic pain.
In conclusion, despite the promising results from the initial gene association studies, the evidence of an association between the COMT polymorphism and the opioid dose in chronic cancer pain is not convincing.
Miscellaneous studies
The systematic review included a number of studies that could not be incorporated into any of the meta-analyses because of the different pain types on which they focused. Therefore, we summarize them here rather than in the results section. Armero et al. [74] studied neuropathic pain in a Spanish population, and they found no association between the susceptibility to neuropathic pain of different origins and rs4680. Persistent postoperative pain is likely related to neuropathic pain. Lee et al. [44] suggested that rs4818 and rs6269, but not rs4680, may be linked to long-lasting postsurgical pain after the removal of a third molar in a Caucasian Irish population. However, Hickey et al. [45] suggested that there may be a link between rs4680 and persistent pain after mastectomy in Irish patients, and Fernández-de-lasPeñas et al. [46] showed an association between rs4680 and elevated pain ratings in mastectomized Spanish breast cancer survivors. Similarly, the COMT polymorphism was not found to affect the gene Â pain interaction with mood in postdiscectomy sciatic pain patients [86] . Together, these findings suggest that rs4680 is not linked to the probability of developing a pain condition that involves nerve damage. However, other COMT polymorphisms could still contribute toward the risk of neuropathic pain.
Multisomatoform disorder is characterized as a minimum of three medically unexplained, currently troublesome ailments that are accompanied by more than a 2-year history of somatization [87] . These patients show a higher prevalence of psychiatric comorbidity, worse functioning, and impaired symptom improvement compared with individuals without the disorder [88] . A recent study attempted to elucidate the possible genetic risk factors of this relatively unknown disease by exploring the association between six SNPs in the COMT gene, including rs4680 [58] . None of the SNPs investigated was found to be associated with multisomatoform disorder. However, it is likely that there is no single gene that would be clearly linked to this complex disorder. This negative finding does not exclude the possibility that the COMT polymorphism could affect a better-defined aspect of pain sensitivity in the multisomatoform disorder.
Temporomandibular joint disease, which is defined by pain in the head and neck muscles that is related to chewing movements, pain in the temporomandibular joint, and limitations in jaw movements [89] , is one type of musculoskeletal pain condition. We found only one paper that had studied the association between the COMT polymorphism and temporomandibular joint disease in a Caucasian American population [29] . Because it was designed to explore the association between high (HPS), average (APS), or low (LPS) pain sensitivity polymorphism and the risk of temporomandibular joint disease, we could not, unfortunately, group it together with studies using only single SNPs. These haplotypes are formed from SNPs rs6269, rs4633, rs4818, and rs4680. The pain sensitivity haplotypes were named on the basis of how sensitive the carriers of each haplotype were to acute experimental pain [29] . Diatchenko et al. [29] found that the presence of even one LPS haplotype significantly reduces the risk of temporomandibular joint disease. Although rs4680 was found to moderate the psychological factors that affect fibromyalgia pain [49, 50] , pain sensitivity haplotypes of COMT did not seem to regulate the psychological factors that were linked to pain sensitivity in temporomandibular joint disease [70] . Instead, it could possibly modulate the effect of propranolol therapy in the treatment of temporomandibular joint disease in Caucasian women [71] .
General mechanistic discussion
There are several hypotheses on how the inhibition and/or the decrease of COMT activity would affect nociception. The impact of COMT is primarily believed to be related to its role as an enzyme metabolizing catecholamines, notably dopamine. Besides rs4680, a few other SNPs may also affect the enzymatic activity of COMT. At least SNPs rs4633, rs737865, rs165599, rs2097603 (presently known as rs2075507), and rs6267 have been shown to have an effect on COMT activity in vitro [20, [90] [91] [92] [93] . Consequently, these SNPs have been studied for their role in nociception. The potential mechanisms of altered methylation activity may be a change in the expression (rs4633, rs737865, and rs165599 [90, 91] ) or transcription (rs737865, rs2020917 [92] ) of the COMT gene. In addition to genetic engineering of the COMT gene, COMT inhibitors can also reduce COMT activity significantly. To our knowledge, the effects of COMT inhibitors on pain have not been characterized in humans. They may have actions beyond COMT inhibition, and therefore, some particular properties of COMT inhibitors, relevant for pain, will be discussed later. As catecholamines are essential components of both the ascending and the descending pain tracts, changes in catecholamine levels may modify nociception up and down.
COMT is expressed in the following structures: (a) the prefrontal cortex and several other brain regions, (b) the spinal cord, for example in the superficial laminae of the dorsal horn of the spinal cord, and (c) peripheral structures, such as the ganglia of the primary sensory neurons [94, 95] , all of which are involved in the processing of nociception or pain perception. In the periphery, low COMT activity that leads to enhanced catecholaminergic tone is evidently nociceptive [30, 96] . In the spinal cord and the brain, the situation is reverse: low COMT (high dopaminergic tone) appears to be antinociceptive [97] and associated with lower COMT activity in brain regions processing cognitive aspects of pain in response to a painful thermal stimulation of skin [98] . In addition, at least the effect of COMT activity on opioid-related analgesia depends on the pain model, and in humans, it also depends on the cause of pain; cancer pain may be different from transient postoperative pain and chronic pain forms. Increased pain sensitivity may not necessarily be observed under normal conditions in the absence of nociceptive stimuli, but instead, the pain symptoms that are related to pathological conditions are enhanced. This scenario could lead to a higher probability of reporting such symptoms and overdiagnosis of chronic pain conditions in patients.
A monoamine oxidase-dependent catecholamine metabolite, 3,4-dihydroxyphenyl-glycolaldehyde (DOPEGAL), produces mechanical hyperalgesia [99] . DOPEGAL is metabolized by aldehyde reductase to 3,4-dihydroxyphenylglycol and is further O-methylated by COMT. If COMT activity is compromised, then DOPEGAL may accumulate, acting as a pain inducer. Unfortunately, some of the original results have been retracted [100] , and the role of this intriguing nociceptive metabolite remains unclear.
Initially, it was suggested that the enhancing effects of low COMT activity on morphine analgesia are mediated through dopamine-triggered compensatory changes in the endogenous opioid system in the brain [83] . This hypothesis has later received some support from studies in humans. Notably, a low COMT activity would increase the amount of opioid receptors, as suggested by previous studies, and hence may enhance supraspinal responses to exogenous opioids [83, 84] . Thus, even if low COMT activity decreases opioid peptide mRNA in the shell region of the nucleus accumbens, as observed in the study of Nikoshkov et al. [101] , the change was not confirmed by Berthele et al. [84] , and it was not sufficient to produce measurable behavioral changes in the stress-induced analgesia assay [26] . Recently, Kowarik et al. [102] have shown that there was a positive correlation between morphine receptor binding and morphine receptor expression levels, and a negative correlation between met-enkephalin peptide and pro-pre-enkephalin mRNA expression levels across the post-mortem globus pallidum samples that have different rs4680 genotypes.
The periaqueductal gray (PAG) plays an important role in nociceptive modulation, and alterations in neural transmission within the PAG modify the antinociceptive effects of morphine [103] . There is a network of dopaminergic neurons within the ventral periaqueductal gray (vPAG). This network is a part of the dorsocaudal A10 group [104] . Dopamine neurons may communicate with neural areas that are involved in the affective aspects of pain [105, 106] . Dopaminergic neuron depletion in the vPAG with 6-hydroxydopamine (6-OHDA) decreases opioid-induced antinociception in rats [107] , and a more recent study suggests that dopamine may have a direct antinociceptive effect in addition to the modulation of the antinociceptive effects of morphine [108] . Both D 1 and D 2 dopamine receptors are expressed by PAG neurons; the former receptors are associated with morphine analgesia [107] and the latter receptors are associated with dopamine analgesia [108] . It has been suggested that there are synaptic connections between dopaminergic and GABAergic neurons in the vPAG, which implicates the participation of dopaminergic neurons in analgesia. Considering the involvement of vPAG dopaminergic neurons in the response to opioid drugs, a recent sleep deprivation study is of interest [109] . Increased pain perception and attenuated antinociceptive effects of morphine were found to be associated with low tyrosine hydroxylase staining in the PAG. This situation was effectively reversed by L-dopa treatment.
Elevated levels of catecholamines are generally associated with the descending inhibition of pain in the spinal dorsal horn [110] , and the antidepressants used to treat persistent pain conditions are believed to act by increasing the synaptic level of catecholamines at the spinal level [111, 112] . Finally, stress-induced and opioidinduced analgesia was attenuated only in the tail flick test, which purely measures a spinal withdrawal reflex that is maintained even after spinal transection [113] .
Several types of COMT inhibitors, even those that do not suppress COMT activity in the brain, produced pronociceptive effects. The pronociceptive effects of COMT inhibitors have been blocked by b 2/3 -antagonists and have been attributed to the activation of peripheral b 2/3 -adrenergic receptors [30] . This scenario was indirectly supported by other studies that showed that those receptors mediate adrenaline-induced hyperalgesia [96] . The administration of opioids activates the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, causing an elevation in peripheral catecholamines [114] . Opioids, when administered at lower doses, have been shown to counteract analgesia or even to produce hyperalgesia that is mediated through peripheral/spinal b-adrenergic receptors [115] . Correspondingly, in human volunteers, opioid hyperalgesia was increased in patients with low COMT activity (see below, [85] ). With respect to the pronociceptive action of COMT inhibition, changes in opioid transmission do not explain all of the effects of COMT inhibitors, and therefore, other or supplementary mechanisms have been suggested [26, 30] .
Because it is obvious that low COMT activity is nociceptive, it is challenging to explain why nitecapone, a mainly peripherally acting COMT inhibitor, exerted an opposite effect: it alleviated neuropathic pain in two rat models: diabetic neuropathy [31] and the spinal nerve ligation [33] . The unexpected but clear antiallodynic and antihyperalgesic effect of nitecapone in diabetic neuropathy has been explained by the attenuation of the spontaneous activity of a wide dynamic range of neurons in the spinal dorsal horn [31] . An electrophysiological study showed that a fairly high dose of OR-486 (30 mg/kg, intravenously) reduced spinal responses to nociceptive stimulation and spinal long-term potentiation [97] . The antihyperalgesic effect of nitecapone was not dependent on a 2 -adrenoceptors or opioid receptors [31] ; however, anatomical facts and the distribution of adrenergic receptors should be seriously considered. For example, the densities of adrenergic b 2/3 -receptors are low in the dorsal root ganglion but high in the peripheral tissues as well as in many parts of the brain [30, 116] . A local spinal noradrenergic stimulation produced antinociception [117] [118] [119] . In addition, dopamine D 2 receptor stimulation is antinociceptive [120] [121] [122] . As mentioned above, the beneficial spinal action of COMT inhibitors is strongly supported by the direct measurements of C-fiber responses from the dorsal horn after a single dose of OR-486 [97] . The spinal action of COMT inhibitors would become possible in this specific ligation model, where the blood-spinal cord barrier could be mechanically damaged at the site of the injury [123] . It is noteworthy that a direct intrathecal administration of nitecapone caused some antinociception in the rat [32] .
In animal models of neuropathic pain, free radical scavengers have reduced the phosphorylation of NMDA receptors, central sensitization, allodynia, and hyperalgesia [124] [125] [126] . Nitecapone indeed scavenges reactive oxygen and nitric oxide species and prevents lipid peroxidation at clinically relevant concentrations [127] [128] [129] [130] [131] . Several studies have suggested that oxidative stress is involved in neuropathic and other persistent pains [125, [132] [133] [134] . Thus, the antioxidative properties of nitecapone can contribute toward its antihyperalgesic effects.
Conclusion
Low COMT activity has been associated with increased pain sensitivity in human pain studies, and COMT inhibitors sensitize to thermal and mechanical pain in animal studies. Low COMT activity haplotypes, rather than any single SNP alone, are associated with human pain. In chronic clinical pain, the effects of COMT polymorphisms depend on the pain conditions. COMT activity does not affect pain sensitivity in neuropathic and cancer pains, but the situation may be different in other chronic pain conditions. Results from the meta-analyses show that rs4680 is significantly associated only with fibromyalgia or chronic widespread pain but not with migrainous headache or chronic musculoskeletal pain conditions. Low COMT activity may, however, enhance opioid analgesia and exacerbate adverse effects, at least in some cancer pains. Low COMT levels in the spinal cord and brain may even favor antinociception under some specific conditions. In support of this hypothesis, nitecapone acts as an analgesic in animal models of neuropathy.
Strengths and weaknesses of the meta-analysis
The main limitation of this systematic review and metaanalysis is the small number of existing studies and thus the small sample size in each meta-analysis. This inevitably decreases the power of the analysis and may affect heterogeneity. It could also affect publication bias, although this was not a problem in our analyses. We observed some heterogeneity in the fibromyalgia/chronic widespread pain and musculoskeletal pain material. In the fibromyalgia/chronic widespread pain group, the heterogeneity is likely because of different ethnic groups. In the musculoskeletal pain group, the heterogeneity is most probably derived as a result of the wide variety of pains collected under one title -the pains vary from osteoarthritis-related pain to low back pain to musclederived chest pain. The reasons for and the mechanisms of these pains can be diverse and, in the case of the study of Hagen and coworkers, the possibility of fibromyalgia could not be excluded. Heterogeneity has been taken into account with the use of a random effects model of meta-analysis and by attempting to clarify the reasons for it. We also regret that we could not analyze other SNPs than rs4680 because especially including haplotypes would have been informative. The strength of this review is that we have analyzed the effect of COMT rs4680 on several different pain types and also attempted to explain the findings on the basis of the existing human and animal literature. In the future, we hope to find goodquality replication studies on the association between the COMT Val158Met polymorphism and different types of pain, possibly also including haplotypes containing the rs4680 SNP. These would considerably benefit subsequent efforts to summarize COMT gene association data.
